- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06890338
En studie for å vurdere antitumoraktivitet av intravenøst (IV) tilførte karboplatin med mirvetuximab soravtansin hos deltakere med nylig diagnostisert folatreseptor alfa (FRa) som uttrykker avansert stadium serøs epitelskift, eggleder eller primær peritoneal kreft.
En enkeltarm, fase 2-studie av neoadjuvant karboplatin og mirvetuximab soravtansin hos personer med FRa-uttrykkende avansert stadium serøs epitel ovarie, eggledere eller primær peritoneal kreft
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous epithelial ovarian, fallopian tube or primary peritoneal cancer (EOC).
Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to cancer cells carrying a protein called folate receptor alpha (FRα). This is a single arm study in adult participants with advanced-stage Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) III-IV FRα-expressing serous EOC. Around 140 participants will be enrolled in the study at approximately 80 sites in the United States.
Participants will receive intravenous infusion of MIRV in combination with carboplatin on day 1 of each cycle, every 21 days for up to 6 - 9 Cycles. The total study duration will be approximately 3 years .
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: ABBVIE CALL CENTER
- Telefonnummer: 844-663-3742
- E-post: abbvieclinicaltrials@abbvie.com
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35294
- Rekruttering
- University of Alabama at Birmingham (UAB) Hospital /ID# 274793
-
Mobile, Alabama, Forente stater, 36604
- Rekruttering
- Usa Mitchell Cancer Institute /ID# 276022
-
-
California
-
Irvine, California, Forente stater, 92618
- Rekruttering
- Kaiser Permanente - Irvine /ID# 276924
-
Los Angeles, California, Forente stater, 90095
- Rekruttering
- UCLA - University of California Los Angeles Medical Center /ID# 274566
-
San Diego, California, Forente stater, 92103
- Rekruttering
- Scripps Md Anderson - Prebys Cancer Center /ID# 276891
-
San Francisco, California, Forente stater, 94109
- Rekruttering
- California Pacific Medical Center - Van Ness Campus /ID# 275329
-
Santa Barbara, California, Forente stater, 93105
- Aktiv, ikke rekrutterende
- Ridley Tree Cancer Center /ID# 275219
-
-
Connecticut
-
Danbury, Connecticut, Forente stater, 06810
- Rekruttering
- Danbury Hospital, Western Connecticut Health Network /ID# 274783
-
New Haven, Connecticut, Forente stater, 06510
- Rekruttering
- Yale University School of Medicine /ID# 275794
-
Norwalk, Connecticut, Forente stater, 06856
- Rekruttering
- Norwalk Hospital /ID# 274561
-
-
Florida
-
Jupiter, Florida, Forente stater, 33458
- Rekruttering
- Jupiter Medical Center /ID# 276616
-
Miami Beach, Florida, Forente stater, 33140
- Fullført
- Mount Sinai Medical Center /ID# 274868
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60607
- Rekruttering
- Rush Md Anderson Cancer Center /ID# 274926
-
Chicago, Illinois, Forente stater, 60637
- Rekruttering
- University of Chicago Medical Center /ID# 274796
-
Peoria, Illinois, Forente stater, 61637-0001
- Rekruttering
- OSF St. Francis Medical Center /ID# 274752
-
Urbana, Illinois, Forente stater, 61801
- Rekruttering
- Carle Foundation Hospital /ID# 276470
-
-
Indiana
-
Fort Wayne, Indiana, Forente stater, 46845
- Rekruttering
- Parkview Research Center /ID# 274338
-
Indianapolis, Indiana, Forente stater, 46202
- Rekruttering
- Indiana University Melvin and Bren Simon Cancer Center /ID# 275492
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40503
- Rekruttering
- Baptist Health Lexington /ID# 275218
-
Louisville, Kentucky, Forente stater, 40207
- Rekruttering
- Norton Cancer Institute - St. Matthews /ID# 276173
-
-
Louisiana
-
Covington, Louisiana, Forente stater, 70433
- Rekruttering
- Women'S Cancer Care /ID# 276469
-
New Orleans, Louisiana, Forente stater, 70112
- Rekruttering
- University Medical Center New Orleans /ID# 274755
-
Shreveport, Louisiana, Forente stater, 71103
- Rekruttering
- Willis-Knighton Medical Center /ID# 274310
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21201
- Rekruttering
- University of Maryland, Baltimore /ID# 275308
-
Silver Spring, Maryland, Forente stater, 20910
- Rekruttering
- Holy Cross Hospital /ID# 275872
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55455-0341
- Rekruttering
- University of Minnesota - Minneapolis /ID# 275718
-
Saint Louis Park, Minnesota, Forente stater, 55416
- Rekruttering
- Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 274780
-
-
Mississippi
-
Jackson, Mississippi, Forente stater, 39216
- Rekruttering
- University Of Mississippi Medical Center /ID# 276342
-
-
Missouri
-
Springfield, Missouri, Forente stater, 65807
- Rekruttering
- Cox Medical Center South /ID# 274826
-
St Louis, Missouri, Forente stater, 63141
- Rekruttering
- Mercy David C. Pratt Cancer Center /ID# 275655
-
-
Nevada
-
Reno, Nevada, Forente stater, 89511
- Rekruttering
- The Center Of Hope /ID# 274313
-
-
New Hampshire
-
Lebanon, New Hampshire, Forente stater, 03756
- Rekruttering
- Dartmouth-Hitchcock Medical Center /ID# 274676
-
-
New Jersey
-
Hackensack, New Jersey, Forente stater, 07601
- Rekruttering
- John Theurer Cancer Center /ID# 275756
-
New Brunswick, New Jersey, Forente stater, 08901
- Rekruttering
- Rutgers Cancer Institute of New Jersey /ID# 274358
-
Teaneck, New Jersey, Forente stater, 07666
- Rekruttering
- Holy Name Medical Center /ID# 276240
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87109
- Rekruttering
- Optimum Clinical Research Group /ID# 274583
-
-
New York
-
Bay Shore, New York, Forente stater, 11706
- Rekruttering
- Imbert Cancer Center /ID# 275634
-
Greenlawn, New York, Forente stater, 11740
- Rekruttering
- Northwell Health Cancer Institute At Huntington /ID# 276814
-
Lake Success, New York, Forente stater, 11042
- Rekruttering
- Northwell Health Center for Advanced Medicine. /ID# 275641
-
New York, New York, Forente stater, 10032
- Rekruttering
- Columbia University Irving Medical Center /ID# 276156
-
Rego Park, New York, Forente stater, 11374
- Rekruttering
- Northwell Health Queens Cancer Center /ID# 274850
-
West Islip, New York, Forente stater, 11795
- Rekruttering
- Good Samaritan Hospital Medical Center /ID# 274938
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27514
- Rekruttering
- University of North Carolina Medical Center /ID# 275307
-
Charlotte, North Carolina, Forente stater, 28204
- Rekruttering
- Atrium Health Levine Cancer Institute /ID# 274557
-
Greenville, North Carolina, Forente stater, 27834
- Rekruttering
- East Carolina University - Brody School of Medicine /ID# 275770
-
Winston-Salem, North Carolina, Forente stater, 27157
- Rekruttering
- Atrium Health Wake Forest Baptist Medical Center /ID# 276952
-
-
North Dakota
-
Fargo, North Dakota, Forente stater, 58102
- Rekruttering
- Sanford Fargo Medical Center - Fargo /ID# 275489
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44195
- Rekruttering
- Cleveland Clinic - Cleveland /ID# 276133
-
Cleveland, Ohio, Forente stater, 44195
- Rekruttering
- Cleveland Clinic - Cleveland /ID# 278273
-
Cleveland, Ohio, Forente stater, 44195
- Rekruttering
- Cleveland Clinic - Cleveland /ID# 278274
-
Cleveland, Ohio, Forente stater, 44109
- Rekruttering
- Metrohealth Medical Center - Cleveland /ID# 276664
-
Columbus, Ohio, Forente stater, 43219
- Rekruttering
- The Mark H Zangmeister Center /ID# 275106
-
Kettering, Ohio, Forente stater, 45429
- Rekruttering
- Kettering Medical Center /ID# 274365
-
-
Oregon
-
Eugene, Oregon, Forente stater, 97401
- Rekruttering
- Oncology Associates of Oregon, P.C. /ID# 275006
-
Tigard, Oregon, Forente stater, 97223
- Rekruttering
- Compass Oncology - West - Tigard /ID# 275101
-
Ta kontakt med:
- Site Coordinator
- Telefonnummer: (971) 708-7600
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Forente stater, 18015
- Rekruttering
- St. Lukes University Hospital /ID# 274362
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Rekruttering
- University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275612
-
Pittsburgh, Pennsylvania, Forente stater, 15224
- Rekruttering
- West Penn Hospital /ID# 276028
-
-
Rhode Island
-
Providence, Rhode Island, Forente stater, 02905
- Rekruttering
- Women & Infants Hospital /ID# 274716
-
-
South Dakota
-
Sioux Falls, South Dakota, Forente stater, 57105
- Rekruttering
- Avera Cancer Institute - Sioux Falls /ID# 276226
-
Sioux Falls, South Dakota, Forente stater, 57104
- Rekruttering
- Sanford Cancer Center /ID# 274901
-
-
Texas
-
Austin, Texas, Forente stater, 78731
- Rekruttering
- Texas Oncology - Austin Central /ID# 275046
-
Fort Worth, Texas, Forente stater, 76104
- Rekruttering
- Texas Oncology - Fort Worth Cancer Center /ID# 275043
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Houston Methodist Hospital /ID# 274568
-
Ta kontakt med:
- Site Coordinator
- Telefonnummer: 713.441.3250
-
San Antonio, Texas, Forente stater, 78240
- Rekruttering
- Texas Oncology - San Antonio Medical Center - Research Drive /ID# 275090
-
The Woodlands, Texas, Forente stater, 77380
- Rekruttering
- Texas Oncology - The Woodlands /ID# 275015
-
Tyler, Texas, Forente stater, 75702
- Rekruttering
- Texas Oncology - Northeast Texas /ID# 275057
-
-
Virginia
-
Charlottesville, Virginia, Forente stater, 22903
- Rekruttering
- UVA Health University Hospital /ID# 275309
-
Fairfax, Virginia, Forente stater, 22031
- Rekruttering
- Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 276456
-
Norfolk, Virginia, Forente stater, 23502-2800
- Rekruttering
- Virginia Oncology Associates- Norfolk (Brock) /ID# 275227
-
Roanoke, Virginia, Forente stater, 24014
- Rekruttering
- Carilion Roanoke Memorial Hospital /ID# 274684
-
-
Washington
-
Spokane, Washington, Forente stater, 99204
- Rekruttering
- Providence Sacred Heart Medical Center & Children'S Hospital /ID# 274585
-
-
West Virginia
-
Morgantown, West Virginia, Forente stater, 26506
- Rekruttering
- West Virginia University School of Medicine /ID# 274556
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
-
Be judged by the investigator and/or treating physician to be an appropriate candidate to receive neoadjuvant chemotherapy.
-
Diagnosis of biopsy-confirmed high-grade, serous epithelial ovarian, fallopian tube or primary peritoneal cancer.
-
Participant meets the following disease criteria:
- Stage III or IV disease by the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) staging system, and
- Folate Receptor Alpha (FRα) expression positivity as defined by immunohistochemical staining of >= 75% of viable tumor cells with moderate >= 2+ membrane staining by the Ventana Folate Receptor Alpha (VENTANA FOLR1) assay, FOLR1 Eligibility Testing - Ventana FOLR1 (FOLR1-2.1) RxDx - Commercial or Central, and
- Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria.
Exclusion Criteria:
-
Endometrioid, clear cell, mucinous, or sarcomatous tumor histology; mixed tumors containing any of the above histologies; or low-grade/borderline ovarian tumor.
-
Previous clinical diagnosis of noninfectious interstitial lung disease, including noninfectious pneumonitis.
-
Previously treated with anticancer therapy including chemotherapy, radiation therapy, immunotherapy, or biologic agent for current cancer, with the exception of one cycle of single agent carboplatin
-
Participants with the following ocular history and/or concurrent disorders:
- History of corneal transplantation;
- Undergoing active postoperative management for refractive surgery, cataract surgery, corneal cross-linking, or corneal complications of surgery;
- Confluent superficial punctate keratopathy (SPK) not expected to resolve to non-confluence or better within the screening window with standard of care (SOC) intervention;
- Active or chronic clinically significant (>= Grade 3) corneal dystrophy (e.g., Fuchs dystrophy);
- Active ocular conditions requiring ongoing treatment/monitoring, such as glaucoma, which is not adequately controlled with medication or surgery, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema or an ocular condition with high risk of retinal detachment;
- Monocular vision with visual acuity in the worse eye, worse than 20/200 or visual fields less than 20 degrees (i.e., functional blindness in at least one eye).
-
History of other malignancy within 3 years prior to signing study consent. -- Note: Participants with tumors with a negligible risk for metastasis or death (e.g., adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Carboplatin + Mirvetuximab Soravtansine
Participants will receive carboplatin in combination with mirvetuximab soravtansine on Day 1 of a 21-day cycle per dose +/- Bevacizumab per investigator's discretion. |
Intravenous (IV) infusion
Andre navn:
Intravenous (IV) infusion Intravenous (IV) infusion (per investigator's discretion) |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response (OR) by Independent Central Review (ICR)
Tidsramme: Up to Approximately 3 years
|
OR is defined as the best overall response of radiographic complete response (CR) or partial response (PR) as assessed by ICR using RECIST Version 1.1 criteria, prior to any subsequent anticancer therapy, including interval debulking surgery (IDS). |
Up to Approximately 3 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants with Adverse Events (AE)
Tidsramme: Up to Approximately 3 years
|
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug. |
Up to Approximately 3 years
|
|
Percentage of Participants with AEs leading to study drug discontinuation or dose modification
Tidsramme: Up to Approximately 3 years
|
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug. |
Up to Approximately 3 years
|
|
Objective Response (OR) by Investigator
Tidsramme: Up to Approximately 3 years
|
OR is defined as the best overall response of radiographic CR or PR as assessed by investigator using RECIST Version 1.1 criteria, prior to any subsequent anticancer therapy, including IDS. |
Up to Approximately 3 years
|
|
Disease Control by ICR
Tidsramme: Up to Approximately 3 years
|
Disease control defined as CR, PR, or stable disease (SD) as assessed by ICR per RECIST Version 1.1 prior to subsequent anticancer therapy including IDS. |
Up to Approximately 3 years
|
|
Disease control by Investigator
Tidsramme: Up to Approximately 3 years
|
Disease control defined as CR, PR, or stable disease (SD) as assessed by investigator per RECIST Version 1.1 prior to subsequent anticancer therapy including IDS. |
Up to Approximately 3 years
|
|
Percentage of Participants With CA-125 Confirmed Response Per Gynecologic Cancer Intergroup (GCIG) Criteria
Tidsramme: Up to Approximately 3 years
|
The GCIG CA-125 response was defined as at least 50% reduction in CA-125. |
Up to Approximately 3 years
|
|
Progression-Free Survival (PFS) by investigator
Tidsramme: Up to Approximately 3 years
|
PFS by investigator, defined as the time from the date of C1D1 until PD per RECIST v1.1 as assessed by investigator or death from any cause, whichever occurs first. |
Up to Approximately 3 years
|
|
Percentage of Participants that Underwent Interval debulking surgery (IDS)
Tidsramme: Up to Approximately 3 years
|
Percentage of participants that underwent IDS during the course of the study treatment |
Up to Approximately 3 years
|
|
Percentage of participants with complete tumor cytoreduction at IDS
Tidsramme: Up to Approximately 3 years
|
Complete tumor cytoreduction is defined as the absence of macroscopically visible residual disease at the end of the surgery |
Up to Approximately 3 years
|
|
Percentage of participants with Incomplete Tumor Cytoreduction at IDS
Tidsramme: Up to Approximately 3 years
|
Defined as macroscopically visible residual tumor (≤ 1 cm or > 1cm) at the end of surgery. |
Up to Approximately 3 years
|
|
Change from baseline in disease-related symptoms as measured by the NCCN-FACT Ovarian Symptom Index (NFOSI-18) disease symptom subscale - physical (DRS-P)
Tidsramme: Up to Approximately 3 years
|
The NFOSI-18 provides a total score that sums all 18 items, plus 2 multi-item scales that assess physical disease-related symptoms (DRS-P; 9 items) and general function/well-being (F/WB; 3 items). |
Up to Approximately 3 years
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kjønnssykdommer
- Sykdommer i det endokrine systemet
- Urogenitale neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer
- Kvinnelige urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Neoplasmer etter histologisk type
- Kjønnssykdommer, kvinner
- Neoplasmer i endokrine kjertel
- Neoplasmer, kjertel og epitel
- Sykdommer i eggstokkene
- Adnexal sykdommer
- Genitale neoplasmer, kvinnelige
- Gonadal lidelser
- Karsinom
- Eggledersykdommer
- Neoplasmer i eggstokkene
- Karsinom, ovarieepitel
- Egglederneoplasmer
- Aminosyrer, peptider og proteiner
- Proteiner
- Organiske kjemikalier
- Antistoffer, monoklonalt, humanisert
- Antistoffer, monoklonalt
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Koordinasjonskomplekser
- Bevacizumab
- Karboplatin
- mirvetuximab soravtansine
Andre studie-ID-numre
- M25-231
- GOG-3115 (Annen identifikator: GOG)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD-delingstidsramme
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Tilgangskriterier for IPD-deling
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .